Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Status:
RECRUITING
Trial end date:
2025-10-15
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant.
This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo).
The study will include the following stages:
1. Screening, approximately 35 days
2. 42-day Treatment Period
3. 2-week post dose Safety Follow-up Period